Gamble Lena J, Borovjagin Anton V, Matthews Qiana L
Division of Human Gene Therapy, Departments of Medicine, Pathology, Surgery, Obstetrics and Gynecology, The Gene Therapy Center, Birmingham, AL, USA.
Exp Ther Med. 2010 Mar;1(2):233-240. doi: 10.3892/etm_00000037.
The purpose of this article was to review the current strategies of targeted therapy to integrins and define the best course of future research in ovarian cancer targeting. Cell surface integrin targeting has been used as a strategy for targeted therapy of several diseases with some success. The combination of virotherapy and integrin-targeting shows promise as a method for targeting ovarian cancer. More specifically, targeting of ovarian cancer with integrin-directed adenoviruses may lead to therapy with fewer toxicities and side effects. This article offers a review of the benefits of integrin-specific targeted therapy for several diseases and proposes a unique anti-ovarian cancer strategy involving the combination of the above with virotherapy as a potential anti-ovarian cancer treatment.
本文旨在综述目前针对整合素的靶向治疗策略，并确定未来卵巢癌靶向研究的最佳方向。细胞表面整合素靶向已被用作几种疾病靶向治疗的策略，并取得了一定成功。病毒疗法与整合素靶向相结合显示出作为一种靶向卵巢癌方法的前景。更具体地说，用整合素导向腺病毒靶向卵巢癌可能会带来毒性和副作用更少的治疗效果。本文综述了整合素特异性靶向治疗对几种疾病的益处，并提出了一种独特的抗卵巢癌策略，即将上述方法与病毒疗法相结合，作为一种潜在的抗卵巢癌治疗手段。
